VILINBIO
VILINBIO financials
- Market cap
- ₹90 Cr
- Sector
- Healthcare
Quarterly results
Q4 FY26: revenue up 299.5%, net profit up 391.8% against the same quarter last year.
| Line item | Q2 FY23 | Q4 FY23 | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4 | 8 | 8 | 8 | 4 +10% | 10 +26% | 10 +26% | 33 +300% |
| EBITDA | 1 | 1 | 1 | -1 | 0 −62% | 0 −75% | 0 −76% | 3 +602% |
| Net profit | 1 | 1 | 1 | -1 | 0 −78% | 0 −86% | 0 −81% | 2 +392% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +132.6% 1Y
1Y: ₹25.8 on 15 Sept 2025 → ₹60. High ₹60 (16 Sept 2026), low ₹18.95 (16 Dec 2025).
Balance sheet
| Year ending | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | ₹3 Cr | ₹3 Cr | ₹10 Cr | ₹14 Cr | ₹14 Cr | ₹15 Cr |
| Reserves | ₹4 Cr | ₹4 Cr | ₹1 Cr | ₹9 Cr | ₹9 Cr | ₹13 Cr |
| Borrowings | ₹6 Cr | ₹5 Cr | ₹5 Cr | ₹7 Cr | ₹3 Cr | ₹0 Cr |
| Other liabilities | ₹1 Cr | ₹1 Cr | ₹2 Cr | ₹3 Cr | ₹2 Cr | ₹6 Cr |
| Total liabilities | ₹14 Cr | ₹14 Cr | ₹18 Cr | ₹32 Cr | ₹28 Cr | ₹35 Cr |
| Fixed assets | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹3 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹2 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹12 Cr | ₹12 Cr | ₹16 Cr | ₹31 Cr | ₹25 Cr | ₹32 Cr |
| Total assets | ₹14 Cr | ₹14 Cr | ₹18 Cr | ₹32 Cr | ₹28 Cr | ₹35 Cr |
How to read this
As filed on each reporting date, including interim balance sheets. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, promoters trimmed −7.24 pp while the public added +7.24 pp. The shareholder count shrank 22% to 382.
- Promoters
- 56.6%
- Public
- 43.4%
Since Jun 2025
- Promoters −7.24 pp
- Public +7.24 pp
How it drifted, 10 quarters
Over this window promoters fell from 90.5% to 56.6% — −33.8 pp.
Ownership split by quarter, oldest first. Jun '23: Promoters 90.5%, Public 9.6%.Sep '23: Promoters 64.5%, Public 35.5%.Mar '24: Promoters 64.5%, Public 35.5%.Sep '24: Promoters 64.1%, Public 35.9%.Mar '25: Promoters 63.9%, Public 36.1%.Jun '25: Promoters 63.9%, Public 36.1%.Sep '25: Promoters 63.9%, Public 36.1%.Dec '25: Promoters 63.6%, Public 36.4%.Mar '26: Promoters 59.6%, Public 40.4%.Jun '26: Promoters 56.6%, Public 43.4%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Sharaz Shaik +8.65 pp 12.01% held
- Karunakar Reddy Kundoor +3.02 pp 4.38% held
- Glaston Mario Menezes newly disclosed 1.08% held
- Bosco Armando Menezes newly disclosed 1.08% held
- Chenugonipally Maheshwar Reddy newly disclosed 1.08% held
The same filing shows 1 holder trimming and 2 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of VILINBIO above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Sharaz Shaik | 12.01% | +8.65 pp |
| Shankar Reddy Katireddy | 11.68% | unchanged |
| Pravallika Venna | 8.76% | unchanged |
| Allu Ramakrishna Reddy | 7.30% | unchanged |
| Julakanti Naga Avinash Reddy | 5.84% | unchanged |
| Enspire Institute Of Professional Studies Llp | 4.39% | unchanged |
| Karunakar Reddy Kundoor | 4.38% | +3.02 pp |
| Amn Ventures Llp | 4.13% | unchanged |
| Percy Homi Italia | 3.92% | unchanged |
| Mohan Rao Adhi | 3.31% | unchanged |
| Jwala Veeravenkata Panduranga Praneeth | 2.92% | unchanged |
| Krishna | 2.86% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse VILINBIO
Guides on how to read this kind of business and the numbers that matter.